View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 22, 2022updated 27 Jul 2022 12:45pm

Sangamo’s cell therapy receives EC orphan medicinal product designation

TX200 is developed to reduce the transplant rejection risk in HLA-A2 mismatched kidney transplant from a living donor.

This image has an empty alt attribute; its file name is Cytiva-PT-35-1024x87.png

Sangamo Therapeutics has received orphan medicinal product designation (OMPD) from the European Commission (EC) for its Investigational autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy, TX200, for solid organ transplantation.

The latest move follows the receipt of positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA).

TX200 is a collection of autologous regulatory T cells (Tregs) that are engineered to express an HLA-A2 Chimeric Antigen Receptor (CAR) to prevent immune-mediated rejection in HLA-A2 mismatched kidney transplants from a living donor.

It has been developed for reducing the transplant rejection risk by suppressing inflammation in the local area and promoting immunological tolerance.

The cell therapy is being evaluated in patients with HLA-A2 negative receiving a mismatched kidney from a living donor with HLA-A2 positive kidney.

Sangamo Development head Rob Schott said: “Patients who have received a solid organ transplant require lifelong surveillance and chronic immunosuppressive medications to manage the risk of transplant rejection.

“Our goal with TX200 is to create a transformative therapy that reduces the risk of organ rejection while reducing the patient burden from chronic immunosuppressive therapy.

“Achieving this important regulatory milestone takes us one step closer to realising that goal for patients.”

In March, the company dosed the first participant in the Phase I/II STEADFAST clinical study of TX200.

The open-label, multicentre, dose-ranging, single ascending dose study has been designed to evaluate the safety and tolerability of TX200.

In 2020, Sangamo and Novartis signed an exclusive, global licensing collaboration agreement to develop and commercialise genomic therapies for the treatment of neurodevelopmental disorders, including autism.

Free Whitepaper

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology